STX10

Across TCGA pan-cancer cohorts, STX10 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STX10 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STX10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STX10 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where STX10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.327	0.716	.019	12	view →
LUAD	DFS	Quartile	II,III,IV	0.223	0.925	.002	8	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.860	.027	3	view →
HNSC	DFS	Median	III,IV	0.776	0.526	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STX10–CCRCC (DFS)

Open the CCRCC breakdown →